<p>, /PRNewswire/ -- IM Cannabis Corp. (&#34; <strong>IMC</strong>&#34; 或 &#34; <strong>公司</strong>&#34;) (Nasdaq: IMCC) 是一家在以色列和德国运营的医疗大麻公司，今天公布了截至 2026 年 3 月 31 日的第一季度财务业绩。除非另有说明，所有金额均以加元报告。</p>
<p>截至 2026 年 3 月 31 日的三个月内，公司录得收入 870 万美元，毛利润 140 万美元，营业亏损 170 万美元，净亏损 250 万美元，或每股 0.38 美元。公司还继续推进成本优化举措，年度同比减少一般和行政费用 22%。公司还保持对营运资金的严格管理和流动性管理，得益于在截至 2026 年 3 月 31 日的季度内完成的可转换债券融资，以及在季度结束后完成的额外融资。</p>
<p>管理层仍然专注于运营效率、严格的营运资金管理，以及持续评估战略机会以增强公司的长期增长。</p>
<p>完整的中期财务报表和管理层讨论与分析可在 SEDAR+ 和 EDGAR 上获取。</p>
<p><strong>关于 IMC</strong></p>
<p>IMC (Nasdaq: IMCC) 是一家国际公司，专注于在全球市场建立和扩展创新业务和技术。公司目前运营一个医疗大麻平台，为以色列和德国的患者提供服务，同时评估扩展到其他技术驱动行业的机会。</p>
<p>IMC 生态系统通过其子公司在以色列运营，进口和分销大麻给医疗患者，利用多年的专有数据和患者洞察。公司还在以色列运营医疗大麻零售药房和在线平台，确保 IMC 产品在整个价值链中的安全交付和质量控制。在德国，IMC 生态系统通过 Adjupharm GmbH 运营，向药房分销医疗大麻。</p>
<p><strong>前瞻性声明免责声明</strong></p>
<p>本新闻稿包含根据适用的加拿大和美国证券法的前瞻性信息或前瞻性声明（统称为&#34; <strong>前瞻性声明</strong>&#34;）。所有涉及我们预计将来发生的活动或发展的信息均视为前瞻性声明。前瞻性声明通常但不总是通过使用诸如&#34;寻求&#34;、&#34;预期&#34;、&#34;相信&#34;、&#34;计划&#34;、&#34;估计&#34;、&#34;期望&#34;、&#34;可能&#34;和&#34;打算&#34;等词语以及表明某事件或结果&#34;可能&#34;、&#34;将&#34;、&#34;应该&#34;、&#34;可以&#34;或&#34;可能&#34;发生或实现的陈述以及其他类似表达来识别。前瞻性声明基于管理层在声明发布之日的估计和意见。在新闻稿中，此类前瞻性声明包括但不限于与公司的成本优化举措相关的声明；公司在 2026 年减少费用的能力；公司的营运资金纪律和流动性管理；未来融资；战略机会和交易；以及公司在 2026 年的增长。上述前瞻性声明和假设的列表并不详尽。由于前瞻性声明涉及未来事件和条件，其本质上涉及固有的风险和不确定性。实际结果可能与当前预期或前瞻性声明所暗示的结果有重大差异，原因包括：公司未能遵守高度监管行业的适用法规要求；公司运营所在司法管辖区内政府政策和法规的意外变化；公司继续满足纳斯达克资本市场上市要求的能力；任何意外未能保持良好信誉或续期其许可证；公司及其子公司（统称为&#34; <strong>集团</strong>&#34;）履行销售承诺或增长目标的能力；集团依赖第三方供应协议提供足够数量的医疗大麻以履行集团的义务；集团可能面临的责任、相关风险的感知水平，以及涉及集团的任何诉讼或其他类似争议或法律程序的预期结果；竞争加剧的影响；并购机会的缺乏；不利的市场条件；生产数量、质量和成本估算的固有不确定性及意外成本和费用的潜在风险；产品责任和其他与集团大麻产品使用相关的安全责任风险；供应链限制；对关键人员的依赖；现有债务违约的风险；东欧和中东地区战争、冲突和内乱的风险，包括以色列面临的多方战争对公司、其运营和全球医疗大麻行业的影响；公司专注于以色列和德国市场的风险；公司无法实现可持续盈利和/或增加股东价值的风险；公司无法积极管理成本和/或改善利润率的风险；公司无法增长和/或维持销售的风险；公司无法实现其目标和/或战略计划的风险；公司无法降低成本和/或维持收入的风险；以及公司无法利用德国医疗大麻合法化的机会。</p>
<p>请参阅公司截至 2025 年 12 月 31 日的年度报告中 “风险因素” 标题下列出的其他风险、不确定性和因素，该报告可在公司在 SEDAR+ 上的发行人资料（www.sedarplus.ca）和 EDGAR（www.sec.gov/edgar）上获取。本新闻稿中包含的任何前瞻性声明均基于管理层在作出该前瞻性信息时的信念、估计、预期和意见，并以本新闻稿日期为准。除适用证券法要求外，公司不承担更新前瞻性声明的任何义务。投资者不应对前瞻性声明过度依赖。本新闻稿中包含的前瞻性声明受到本警示声明的明确限定。</p>
<p><strong>公司联系方式：</strong></p>
<p>Michal Efraty</p>
<p>投资者与公共关系</p>
<p>[email protected]</p>
<p>Oren Shuster，首席执行官</p>
<p>IM Cannabis Corp.</p>
<p>[email protected]</p>
<p>Logo - https://mma.prnewswire.com/media/1742228/5969528/IM_Cannabis_Logo.jpg</p>
<p>来源 IM Cannabis Corp.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEzJk5ld3NJdGVtSWQ9TE41OTExNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTMxNjAxUFJfTkVXU19VU1BSX19fX19MTjU5MTE3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEzJk5ld3NJdGVtSWQ9TE41OTExNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTMxNjAxUFJfTkVXU19VU1BSX19fX19MTjU5MTE3"/></p>

IMCC

<p>IM Cannabis Corp.（纳斯达克代码：IMCC）公布了 2026 年第一季度的财务业绩，报告收入为 870 万美元，毛利润为 140 万美元，净亏损为 250 万美元。公司将一般和行政费用同比减少了 22%，并专注于成本优化和流动性管理。IMC 在以色列和德国运营，分销医疗大麻并评估扩展机会。新闻稿中包含了关于公司未来计划和潜在风险的前瞻性声明</p>

<p>, /PRNewswire/ -- IM Cannabis Corp. (&#34; <strong>IMC</strong>&#34; or the &#34; <strong>Company</strong>&#34;) (Nasdaq: IMCC), a medical cannabis company with operations in Israel and Germany, today announced its financial results for the first quarter ended March 31, 2026. All amounts were reported in Canadian dollars, unless otherwise stated.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- IM Cannabis Corp. (&#34; <strong>IMC</strong>&#34; 或 &#34; <strong>公司</strong>&#34;) (Nasdaq: IMCC) 是一家在以色列和德国运营的医疗大麻公司，今天公布了截至 2026 年 3 月 31 日的第一季度财务业绩。除非另有说明，所有金额均以加元报告。</p>
</div><p>For the three months ended March 31, 2026, the Company recorded revenues of $8.7 million, gross profit of $1.4 million, operating loss of $1.7 million, and a net loss of $2.5 million, or $0.38 per share. The Company also continued to advance its cost optimization initiatives, reducing general and administrative expenses by 22% year-over-year. The Company also maintained its focus on working capital discipline and liquidity management, supported by convertible note financings completed during the quarter ended March 31, 2026, and additional financings completed following quarter-end.</p>
<div class="lb-trans"><p>截至 2026 年 3 月 31 日的三个月内，公司录得收入 870 万美元，毛利润 140 万美元，营业亏损 170 万美元，净亏损 250 万美元，或每股 0.38 美元。公司还继续推进成本优化举措，年度同比减少一般和行政费用 22%。公司还保持对营运资金的严格管理和流动性管理，得益于在截至 2026 年 3 月 31 日的季度内完成的可转换债券融资，以及在季度结束后完成的额外融资。</p>
</div><p>Management remains focused on operational efficiencies, disciplined working capital management, and the continued evaluation of strategic opportunities to enhance the Company's long-term growth.</p>
<div class="lb-trans"><p>管理层仍然专注于运营效率、严格的营运资金管理，以及持续评估战略机会以增强公司的长期增长。</p>
</div><p>The full Interim Financial Statements and Management's Discussion and Analysis are available on SEDAR+ and EDGAR.</p>
<div class="lb-trans"><p>完整的中期财务报表和管理层讨论与分析可在 SEDAR+ 和 EDGAR 上获取。</p>
</div><p><strong>About IMC</strong></p>
<div class="lb-trans"><p><strong>关于 IMC</strong></p>
</div><p>IMC (Nasdaq: IMCC) is an international company focused on building and scaling innovative businesses and technologies across global markets. The Company currently operates a medical cannabis platform serving patients in Israel and Germany while evaluating opportunities to expand into additional technology-driven sectors.</p>
<div class="lb-trans"><p>IMC (Nasdaq: IMCC) 是一家国际公司，专注于在全球市场建立和扩展创新业务和技术。公司目前运营一个医疗大麻平台，为以色列和德国的患者提供服务，同时评估扩展到其他技术驱动行业的机会。</p>
</div><p>The IMC ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies and online platforms, in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.</p>
<div class="lb-trans"><p>IMC 生态系统通过其子公司在以色列运营，进口和分销大麻给医疗患者，利用多年的专有数据和患者洞察。公司还在以色列运营医疗大麻零售药房和在线平台，确保 IMC 产品在整个价值链中的安全交付和质量控制。在德国，IMC 生态系统通过 Adjupharm GmbH 运营，向药房分销医疗大麻。</p>
</div><p><strong>Disclaimer for Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明免责声明</strong></p>
</div><p>This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, &#34; <strong>forward-looking statements</strong>&#34;). All information that addresses activities or developments that we expect to occur in the future is considered forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as &#34;seek&#34;, &#34;anticipate&#34;, &#34;believe&#34;, &#34;plan&#34;, &#34;estimate&#34;, &#34;expect&#34;, &#34;likely&#34; and &#34;intend&#34; and statements that an event or result &#34;may&#34;, &#34;will&#34;, &#34;should&#34;, &#34;could&#34; or &#34;might&#34; occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to the cost optimization initiatives of the Company; the Company's ability to reduce expenses in 2026; the Company's working capital discipline and liquidity management; future financings; strategic opportunities and transactions; and the Company's growth in 2026. . The above list of forward-looking statements and assumptions is not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company's ability to continue to meet the listing requirements of the Nasdaq Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the &#34; <strong>Group</strong>&#34;) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfill the Group's obligations; the Group's possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group's cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the multi front war that Israel is facing on the Company, its operations and the medical cannabis industry in Israel and globally; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the Company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; and the Company's inability to take advantage of the legalization of medicinal cannabis in Germany.</p>
<div class="lb-trans"><p>本新闻稿包含根据适用的加拿大和美国证券法的前瞻性信息或前瞻性声明（统称为&#34; <strong>前瞻性声明</strong>&#34;）。所有涉及我们预计将来发生的活动或发展的信息均视为前瞻性声明。前瞻性声明通常但不总是通过使用诸如&#34;寻求&#34;、&#34;预期&#34;、&#34;相信&#34;、&#34;计划&#34;、&#34;估计&#34;、&#34;期望&#34;、&#34;可能&#34;和&#34;打算&#34;等词语以及表明某事件或结果&#34;可能&#34;、&#34;将&#34;、&#34;应该&#34;、&#34;可以&#34;或&#34;可能&#34;发生或实现的陈述以及其他类似表达来识别。前瞻性声明基于管理层在声明发布之日的估计和意见。在新闻稿中，此类前瞻性声明包括但不限于与公司的成本优化举措相关的声明；公司在 2026 年减少费用的能力；公司的营运资金纪律和流动性管理；未来融资；战略机会和交易；以及公司在 2026 年的增长。上述前瞻性声明和假设的列表并不详尽。由于前瞻性声明涉及未来事件和条件，其本质上涉及固有的风险和不确定性。实际结果可能与当前预期或前瞻性声明所暗示的结果有重大差异，原因包括：公司未能遵守高度监管行业的适用法规要求；公司运营所在司法管辖区内政府政策和法规的意外变化；公司继续满足纳斯达克资本市场上市要求的能力；任何意外未能保持良好信誉或续期其许可证；公司及其子公司（统称为&#34; <strong>集团</strong>&#34;）履行销售承诺或增长目标的能力；集团依赖第三方供应协议提供足够数量的医疗大麻以履行集团的义务；集团可能面临的责任、相关风险的感知水平，以及涉及集团的任何诉讼或其他类似争议或法律程序的预期结果；竞争加剧的影响；并购机会的缺乏；不利的市场条件；生产数量、质量和成本估算的固有不确定性及意外成本和费用的潜在风险；产品责任和其他与集团大麻产品使用相关的安全责任风险；供应链限制；对关键人员的依赖；现有债务违约的风险；东欧和中东地区战争、冲突和内乱的风险，包括以色列面临的多方战争对公司、其运营和全球医疗大麻行业的影响；公司专注于以色列和德国市场的风险；公司无法实现可持续盈利和/或增加股东价值的风险；公司无法积极管理成本和/或改善利润率的风险；公司无法增长和/或维持销售的风险；公司无法实现其目标和/或战略计划的风险；公司无法降低成本和/或维持收入的风险；以及公司无法利用德国医疗大麻合法化的机会。</p>
</div><p>Please see the other risks, uncertainties and factors set out under the heading &#34;Risk Factors&#34; in the Company's annual report for the year ended December 31, 2025, which is available on the Company's issuer profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company does not undertake any obligation to update forward-looking statements, except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.</p>
<div class="lb-trans"><p>请参阅公司截至 2025 年 12 月 31 日的年度报告中 “风险因素” 标题下列出的其他风险、不确定性和因素，该报告可在公司在 SEDAR+ 上的发行人资料（www.sedarplus.ca）和 EDGAR（www.sec.gov/edgar）上获取。本新闻稿中包含的任何前瞻性声明均基于管理层在作出该前瞻性信息时的信念、估计、预期和意见，并以本新闻稿日期为准。除适用证券法要求外，公司不承担更新前瞻性声明的任何义务。投资者不应对前瞻性声明过度依赖。本新闻稿中包含的前瞻性声明受到本警示声明的明确限定。</p>
</div><p><strong>Company Contact:</strong></p>
<div class="lb-trans"><p><strong>公司联系方式：</strong></p>
</div><p>Michal Efraty</p>
<div class="lb-trans"><p>Michal Efraty</p>
</div><p>Investor &amp; Public Relations</p>
<div class="lb-trans"><p>投资者与公共关系</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>Oren Shuster, CEO</p>
<div class="lb-trans"><p>Oren Shuster，首席执行官</p>
</div><p>IM Cannabis Corp.</p>
<div class="lb-trans"><p>IM Cannabis Corp.</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>Logo - https://mma.prnewswire.com/media/1742228/5969528/IM_Cannabis_Logo.jpg</p>
<div class="lb-trans"><p>Logo - https://mma.prnewswire.com/media/1742228/5969528/IM_Cannabis_Logo.jpg</p>
</div><p>SOURCE IM Cannabis Corp.</p>
<div class="lb-trans"><p>来源 IM Cannabis Corp.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEzJk5ld3NJdGVtSWQ9TE41OTExNyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTMxNjAxUFJfTkVXU19VU1BSX19fX19MTjU5MTE3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LN59117&amp;Transmission_Id=202605131601PR_NEWS_USPR_____LN59117&amp;DateId=20260513"/></p>

IM Cannabis 公司宣布 2026 年第一季度财务业绩